[Federal Register Volume 70, Number 148 (Wednesday, August 3, 2005)]
[Notices]
[Pages 44671-44672]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-15349]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Adaphostin as a Novel 
Cancer Therapy

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in:
    1. E-013-1998/0-US-01, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number 60/076,330 (filed February 27, 1998);
    2. E-013-1998/0-PCT-02, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number PCT/US99/04002 (filed February 24, 1999);

    3. E-013-1998/0-EP-03, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number 99910987.9 (filed February 24, 1999);
    4. E-013-1998/0-JP-04, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number 2000-533395 (filed February 24, 1999);
    5. E-013-1998/0-AU-05, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, patent number 
760046 (filed February 24, 1999);
    6. E-013-1998/0-CA-06, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number 60/076,330 (filed February 24, 1999);

[[Page 44672]]

    7. E-013-1998/0-US-07, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number 09/623,000 (filed February 24, 1999);
    8. E-013-1998/0-EP-08, ``Disubstituted Lavendustin A Analogs and 
Pharmaceutical Compositions Comprising the Analogs'', by Venkatachala 
Narayanan, Edward Sausville, Kaur Gurmeet, Varma Ravi, application 
number 03009396.7 (filed February 24, 1999);

to Ascenta Therapeutics, Inc, which is located in San Diego, CA. The 
patent rights in these inventions have been assigned to the United 
States of America.

    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to human therapeutics for cancer.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 3, 2005 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: John Stansberry, Ph.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5236; Facsimile: (301) 402-0220; E-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The patent applications for this technology 
contain composition of matter claims and method claims for treating 
proliferative diseases. The technology describes tyrphostins, which are 
a class of small molecules that were designed to act as tyrosine kinase 
inhibitors. One of these compounds, adaphostin (NSC 680410), was 
originally identified as an inhibitor of p210Bcr/abl kinase and a 
potent inducer of myeloid cell death in p210B\cr/abl\ -positive K562 
cells in vitro. Recent studies report that adaphostin can induce cell 
death in Bcr/abl-negative leukemia cells, including B-cell chronic 
lymphocytic leukemia. Additional studies have demonstrated that this 
agent might induce cell death through elevation of reactive oxygen 
species (ROS) or down-regulation of VEGF rather than inhibition of 
p210B\cr/abl\. Moreover, adaphostin in combination with other anti-
cancer agents induces apoptosis in CLL-B cells.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 26, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-15349 Filed 8-2-05; 8:45 am]
BILLING CODE 4140-01-P